BiotechTube

Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Conditions

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Trial Timeline

Jan 30, 2025 → May 31, 2032

NCT ID
NCT06374459

About Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab

Zumsemetinib + Capecitabine + Zoledronic acid + Denosumab is a phase 1/2 stage product being developed by United Therapeutics for Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06374459. Target conditions include Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer.

What happened to similar drugs?

9 of 20 similar drugs in Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer were approved

Approved (9) Terminated (2) Active (11)
✅PEG-somatropinSun PharmaceuticalApproved
✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
✅Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Saizen + SaizenMerckApproved
✅Zoledronic Acid + PlaceboNovartisApproved
✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06374459Phase 1/2Recruiting

Competing Products

20 competing products in Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
26
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
44
Enzalutamide + PlaceboAstellas PharmaPhase 3
40
YM598Astellas PharmaPhase 2
27
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
35
PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
39
PEG-somatropinSun PharmaceuticalPhase 3
40
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
35
Somatropin + SomatropinEli LillyPhase 3
40
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
50
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29